Benefit of Interventional Septal Reduction for Hypertrophic Cardiomyopathy: Looking for a Needle in a Haystack?
- PMID: 39367776
- DOI: 10.1111/echo.15952
Benefit of Interventional Septal Reduction for Hypertrophic Cardiomyopathy: Looking for a Needle in a Haystack?
References
-
- E. Arbelo, A. Protonotarios, J. R. Gimeno, et al., “ESC Scientific Document Group. 2023 ESC Guidelines for the Management of Cardiomyopathies,” European Heart Journal 44 (2023): 3503–3626.
-
- M. Y. Desai, A. Owens, K. Wolski, et al., “Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR‐HCM Randomized Clinical Trial,” JAMA Cardiology 8 (2023): 968–977.
-
- T. Lawrenz, D. Lawin, K. Radke, et al., “Acute and Chronic Effects of Endocardial Radiofrequency Ablation of Septal Hypertrophy in HOCM,” Journal of Cardiovascular Electrophysiology 32 (2021): 2617–2624.
-
- Q. Wu, Q. Liang, R. Wang, et al., “Transcoronary Radiofrequency Ablation: A Novel Septal Reduction Option for Hypertrophic Obstructive Cardiomyopathy,” JACC: Cardiovascular Interventions 16 (2023): 725–726.
-
- E. S. Shin, M. K. Chon, E. J. Jun, et al., “Septal Reduction Using Transvenous Intramyocardial Cerclage Radiofrequency Ablation: Preclinical Feasibility,” JACC: Basic to Translational Science 5 (2020): 988–998.
MeSH terms
LinkOut - more resources
Full Text Sources
